Skip to main content
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis

The British Society of Rheumatology's 2025 Gu

Dr. John Cush RheumNow

8 months 3 weeks ago
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj
UK study of 1846 RA pts starting a b/tsDMARDs, ~30% on steroids & majority (2/3) continued use over the first year o

Dr. John Cush RheumNow

8 months 3 weeks ago
UK study of 1846 RA pts starting a b/tsDMARDs, ~30% on steroids & majority (2/3) continued use over the first year of new novel treatment. This suggests these aer either severe RA pts or that we are not vigilant in limiting/weaning/stopping steroids in RA patients - which is it? https://t.co/TrAktincKT
Japan retrospective study of 38 RA pts who developed MTX assoc lymphoproliferative disorder (LPD) - 22 w/ spontaneous

Dr. John Cush RheumNow

8 months 3 weeks ago
Japan retrospective study of 38 RA pts who developed MTX assoc lymphoproliferative disorder (LPD) - 22 w/ spontaneous regression (SR) vs 16 non-SR (w/ 5 deaths). non-SR Pt had higher LDH levels at Dx & lower lymphocyte recovery 1 mo. post MTX withdrawal & higher mortality risk https://t.co/TRizVwP2BQ
Subcutaneous Anifrolumab Effective in Lupus

A new study published in Arthritis & Rheumatology demonstrates that su

Dr. John Cush RheumNow

8 months 3 weeks ago
Subcutaneous Anifrolumab Effective in Lupus A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients https://t.co/KgBC8vJHuB
2025 Rheumatologists, In Memorium

In 2025, rheumatology lost many of its most influential clinicians, mentors, and coll

Dr. John Cush RheumNow

8 months 3 weeks ago
2025 Rheumatologists, In Memorium In 2025, rheumatology lost many of its most influential clinicians, mentors, and colleagues. This honor roll recognizes those who cared for countless patients, shaped generations of rheumatologists, and left a lasting legacy in our field. As Dr.
2026 Resolutions (1.9.2026)
Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!
Shortened Leukocyte telomere length (PBL-TL) is assoc w/ systemic sclerosis–ILD. Study of PBL-TL in 244 SSc vs 314 co

Dr. John Cush RheumNow

8 months 3 weeks ago
Shortened Leukocyte telomere length (PBL-TL) is assoc w/ systemic sclerosis–ILD. Study of PBL-TL in 244 SSc vs 314 controls, found signif shorter PBL-TL in SSC. Short PBL-TL was assoc w/ ILD & Pulm HTN, more lung related hospitalizations, but not w/ Raynauds, skin or vascular dz
Plenty of evidence that toxic environmental exposures increase #RA risk. Full read, intelligent report from Stanhope et

Dr. John Cush RheumNow

8 months 3 weeks ago
Plenty of evidence that toxic environmental exposures increase #RA risk. Full read, intelligent report from Stanhope et al showing how (healthy environmental) green space exposures are protective & capable of preventing RA!! Lifestyle is gigantically important in your https://t.co/LUWmHhUT7F
Glucocorticoid Injections in Knee Osteoarthritis

A randomized clinical trial of 60 patients found that glucocorticoid

Dr. John Cush RheumNow

8 months 3 weeks ago
Glucocorticoid Injections in Knee Osteoarthritis A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (OA) (compared to https://t.co/4bKAxER0wq
100 women w/ severe preeclampsia (PE) compared to 40 pregnant controls. antiphospholipid antibodies (aPL) was significan

Dr. John Cush RheumNow

8 months 3 weeks ago
100 women w/ severe preeclampsia (PE) compared to 40 pregnant controls. antiphospholipid antibodies (aPL) was significantly more prevalent iin PE women (34% vs 10%) [OR = 4.63]. aPL positivity was also linked to both early and late severe PE [OR = 4-5, p = .008]. https://t.co/YhwplHil1y
Assess Reproductive Health in SLE Clinic Visits Systemic Lupus Erythematosus (SLE) mainly affects women of childbearin

Dr. John Cush RheumNow

8 months 3 weeks ago

Assess Reproductive Health in SLE Clinic Visits Systemic Lupus Erythematosus (SLE) mainly affects women of childbearing age, increasing their risk of infertility, miscarriages, and pregnancy complications due to disease factors and medications. Rheumatologists should actively https://t.co/hqWSpqJ6HN

J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn bl

Dr. John Cush RheumNow

8 months 3 weeks ago
J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn blocker that reduces AutoAbs & B cell activity. Study met its 24 wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://t.co/87FZIogmkW
×